Research Topics
| J E GalvinSummaryAffiliation: Washington University School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cognitive change in Parkinson diseaseJames E Galvin
Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
Alzheimer Dis Assoc Disord 20:302-10. 2006..This review will examine the clinical, cognitive, neuropsychiatric features of cognitive deficits associated with PD, discuss their pathologic basis and propose avenues for future research...- Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic studyJames E Galvin
Department of Neurology, Alzheimer s Disease Research Center, School of Medicine, Washington University, St Louis, MO 63108, USA
Arch Neurol 62:758-65. 2005..To understand the earliest signs of cognitive decline caused by Alzheimer disease (AD) and other illnesses causing dementia, information is needed from well-characterized individuals without dementia studied longitudinally until autopsy... - Psychosocial determinants of intention to screen for Alzheimer's diseaseJames E Galvin
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Alzheimers Dement 4:353-60. 2008..There is little information about how receptive older adults are to discuss memory problems with healthcare providers. Here we test the psychosocial factors explaining older adults' intention to undergo screening for Alzheimer disease (AD)... - The "portable" CDR: translating the clinical dementia rating interview into a PDA formatJames E Galvin
Alzheimer Disease Research Center, Washington University School of Medicine, 4488 ForestPark, Suite 130, St Louis, MO 63108, USA
Alzheimer Dis Assoc Disord 23:44-9. 2009.... - Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigraJames E Galvin
Departments of Neurology, Anatomy and Neurobiology, Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA
Acta Neuropathol 112:115-26. 2006..In this review, we discuss the role of the DA metabolite 3,4-dihydroxyphenylacetaldehyde to provide a plausible link between DA production and metabolism, AS aggregation and the pathogenesis of PD... - Development of a population-based questionnaire to explore psychosocial determinants of screening for memory loss and Alzheimer DiseaseJames E Galvin
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Alzheimer Dis Assoc Disord 20:182-91. 2006.... - The muscle protein dysferlin accumulates in the Alzheimer brainJames E Galvin
Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
Acta Neuropathol 112:665-71. 2006..In muscle, dysferlin plays a role in the repair of muscle membrane damage. The accumulation of dysferlin in the AD brain may be related to the inability of neurons to repair damage due to A beta deposits accumulating in the AD brain... - Clinical phenotype of Parkinson disease dementiaJames E Galvin
Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
Neurology 67:1605-11. 2006..To determine which clinical features best characterize Parkinson disease dementia (PDD), compared with Alzheimer disease (AD) and dementia with Lewy bodies (DLB), and to determine the pathologic basis for PDD... - Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezilJames E Galvin
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
Alzheimer Dis Assoc Disord 22:30-8. 2008..Improved attention may have positive effects on cognitive and functional outcomes for AD patients, although this hypothesis requires further study and validation... - Validity and reliability of the AD8 informant interview in dementiaJames E Galvin
Departments of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
Neurology 67:1942-8. 2006..To establish the validity, reliability, and discriminative properties of the AD8, a brief informant interview to detect dementia, in a clinic sample... - Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementiaJames E Galvin
Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA
Arch Neurol 64:725-30. 2007..To test the ability of patients to rate their own cognitive ability using the AD8 compared with informant and clinician ratings of cognitive status... - Expression profiling in the aging brain: a perspectiveJames E Galvin
Department of Neurology, Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63108, USA
Ageing Res Rev 4:529-47. 2005.... - Evaluation of cognitive impairment in older adults: combining brief informant and performance measuresJames E Galvin
Department of Neurology, Washington University, St Louis, Missouri 63108, USA
Arch Neurol 64:718-24. 2007..To combine the AD8, a brief informant interview, with performance measures to develop a brief screening tool to improve detection of cognitive impairment and dementia in general practice... - The AD8: a brief informant interview to detect dementiaJ E Galvin
Department of Neurology, Alzheimer Disease Research Center, Washington University, St Louis, MO 63108, USA
Neurology 65:559-64. 2005..Brief measures that accurately discriminate normal cognitive aging from very mild dementia are lacking. Cognitive tests often are insensitive to very mild dementia. Informant-based measures may be more sensitive in detecting early dementia... - Synucleinopathies: clinical and pathological implicationsJ E Galvin
Alzheimer s Disease Research Center, Department of Neurology, Campus Box 8111, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
Arch Neurol 58:186-90. 2001..Furthermore, these efforts will likely lead to novel diagnostic and therapeutic strategies in regard to the synucleinopathies... - Lewy body dementia: caregiver burden and unmet needsJames E Galvin
Department of Neurology, Washington University, St Louis, MO, USA
Alzheimer Dis Assoc Disord 24:177-81. 2010..Community resources such as the Lewy Body Dementia Association may serve this end, while also providing practical information and support for caregivers... - Familial dementia with Lewy bodies: clinicopathologic analysis of two kindredsJ E Galvin
Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
Neurology 59:1079-82. 2002..Familial DLB is clinically heterogeneous and occurs with or without coexistent AD, suggesting the relevance of LB pathology for the developing dementia... - Personality traits distinguishing dementia with Lewy bodies from Alzheimer diseaseJames E Galvin
Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
Neurology 68:1895-901. 2007..To identify personality traits that distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD)... - Dementia with Lewy bodiesJames E Galvin
Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
Arch Neurol 60:1332-5. 2003 - Neurodegenerative diseases: pathology and the advantage of single-cell profilingJames E Galvin
Alzheimer s Disease Research Center, Department of Neurology and Anatomy, Washington University School of Medicine, St Louis, Missouri 63108, USA
Neurochem Res 29:1041-51. 2004..The pathologic features of neurodegenerative diseases are first discussed followed by a rationale behind sampling mRNA species from single cells rather than from whole-brain homogenates to explore disease mechanisms... - Expression profiling and pharmacotherapeutic development in the central nervous systemJames E Galvin
Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
Alzheimer Dis Assoc Disord 18:264-9. 2004..This is a difficult task that demands a multidisciplinary approach that is highlighted in this review within the context of neurodegenerative pathology... - Predictors of physician referral for patient recruitment to Alzheimer disease clinical trialsJames E Galvin
Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri 63108, USA
Alzheimer Dis Assoc Disord 23:352-6. 2009..The majority of dementia patients are first evaluated by community-based physicians; however, physician perceptions of clinical research are largely unknown... - The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signsJ M Burns
Department of Neurology, Washington University, St Louis, MO, USA
Neurology 64:1397-403. 2005..Extrapyramidal signs (EPS) are common in Alzheimer disease (AD) and increase in prevalence as AD advances. The neuropathologic substrate responsible for EPS in AD remains to be fully characterized... - Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathologyJ E Galvin
Department of Neurology, Medical College of Pennsylvania Hahnemann University the Center for Neurodegenerative Disease Research, and the Department of Neurology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
Am J Pathol 157:361-8. 2000..These findings expand the concept of neurodegenerative synucleinopathies by implicating alphaS, betaS, and gammaS in the pathogenesis of NBIA 1... - Cognitive profiles in dementia: Alzheimer disease vs healthy brain agingD K Johnson
Alzheimer Disease Research Center, Washington University, St Louis, MO 63108, USA
Neurology 71:1783-9. 2008..To re-examine proposed models of cognitive test performance that concluded separate factor structures were required for people with Alzheimer disease (AD) and older adults without dementia... - Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synucleinJ E Galvin
Department of Neurology, Medical College of Pennsylvania, Hahnemann University, 245 North 15th Street, Philadelphia, PA 19129, USA
Proc Natl Acad Sci U S A 96:13450-5. 1999..Our findings broaden the concept of neurodegenerative "synucleinopathies" by implicating betaS and gammaS, in addition to alphaS, in the onset/progression of PD and DLB... - Verbal and visuospatial deficits in dementia with Lewy bodiesDavid K Johnson
Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA
Neurology 65:1232-8. 2005..Both visuospatial and verbal abilities declined at similar rates across the three patient groups. DLB diagnosis may be improved, particularly when there is comorbid AD, by using domain-specific testing... - Relationship of dementia screening tests with biomarkers of Alzheimer's diseaseJames E Galvin
Alzheimer s Disease Research Centre, Washington University, St Louis, MO 63108, USA
Brain 133:3290-300. 2010.... - Effect of cognitive fluctuation on neuropsychological performance in aging and dementiaAdriana Escandon
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Neurology 74:210-7. 2010..Fluctuations are a core feature of dementia with Lewy bodies, but the impact of fluctuations in healthy brain aging and Alzheimer disease (AD) are unknown... - Longitudinal study of the transition from healthy aging to Alzheimer diseaseDavid K Johnson
Department of Psychology, University of Kansas, Lawrence, Kansas City, Missouri, USA
Arch Neurol 66:1254-9. 2009..Detection of the earliest cognitive changes signifying Alzheimer disease is difficult... - Distinguishing Lewy body dementias from Alzheimer's diseaseRawan Tarawneh
Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
Expert Rev Neurother 7:1499-516. 2007..Improved understanding of disease mechanisms may open new therapeutic avenues for LBD in the future... - Neuroanatomical predictors of response to donepezil therapy in patients with dementiaJohn G Csernansky
Alzheimer s Disease Research Center, and Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
Arch Neurol 62:1718-22. 2005..Patients with dementia of the Alzheimer type (DAT) respond variably to treatment with acetylcholinesterase inhibitors... - Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigraJ E Galvin
Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
Exp Neurol 168:347-55. 2001.... - Detection of aggregates and protein inclusions by staining of tissuesJames E Galvin
The Alzheimer's Disease Research Center, Department of Neurology, The Washington University School of Medicine, St. Louis, MO, USA
Methods Mol Biol 232:149-64. 2003 - DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkersC F Lippa
Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
Neurology 68:812-9. 2007.... - Survival and mortality differences between dementia with Lewy bodies vs Alzheimer diseaseMonique M Williams
Department of Medicine, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St. Louis, MO 63108, USA
Neurology 67:1935-41. 2006..The greater risk for noncognitive disease progression for DLB compared with AD suggests clinically meaningful differences for the two disorders... - Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJoseph F Quinn
Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
JAMA 304:1903-11. 2010..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology... - Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamineWilliam J Burke
Department of Neurology, Saint Louis VAMC and Saint Louis University Health Sciences Center, St Louis, MO 63125, USA
Acta Neuropathol 115:193-203. 2008..Our findings support the hypothesis that DA metabolism via DOPAL can cause both DA neuron loss and AS aggregation observed in PD... - Potential future neuroprotective therapies for neurodegenerative disorders and strokeRawan Tarawneh
Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA
Clin Geriatr Med 26:125-47. 2010..Although most of these therapies are experimental, and require further investigation, a few seem to offer promise... - The alpha-synuclein mutation E46K promotes aggregation in cultured cellsNeeraj Pandey
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63108, USA
Exp Neurol 197:515-20. 2006..Our results demonstrate that mutations in 4th KTKEGV repeat lead to higher propensity of aggregation of AS compared to other mutants... - Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson diseaseLaurent Seugnet
Washington University School of Medicine, St Louis, MO 63110, USA
Sleep 32:984-92. 2009..Thus we investigated the long-term consequences of sleep deprivation on shortterm memory using a Drosophila model of Parkinson disease... - Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer diseaseAdam S Fleisher
University of California, San Diego, La Jolla, CA 92037, USA
Arch Neurol 65:1031-8. 2008..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease... - Pass the grain; spare the brainJames E Galvin
Neurology 69:1072-3. 2007
Research Grants
- Dementia of Parkinson Type: Clinicopathologic PhenotypeJames Galvin; Fiscal Year: 2004..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..